Abstract
The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) is strictly essential for viral replication and it has been used as viral target for anti-HCV drug development. All small molecules which have been identified to be selective non-nucleoside inhibitors (NNI) of the HCV RdRp to date are reported.
Keywords: HCV, RNA dependent RNA polymerase (RdRp), non-nucleoside, inhibition, drug development, antiviral, NNI, small molecules
Mini-Reviews in Medicinal Chemistry
Title: The Exploding Field of the HCV Polymerase Non-Nucleoside Inhibitors: Summary of a First Generation Compounds
Volume: 8 Issue: 12
Author(s): Enzo Tramontano
Affiliation:
Keywords: HCV, RNA dependent RNA polymerase (RdRp), non-nucleoside, inhibition, drug development, antiviral, NNI, small molecules
Abstract: The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) is strictly essential for viral replication and it has been used as viral target for anti-HCV drug development. All small molecules which have been identified to be selective non-nucleoside inhibitors (NNI) of the HCV RdRp to date are reported.
Export Options
About this article
Cite this article as:
Tramontano Enzo, The Exploding Field of the HCV Polymerase Non-Nucleoside Inhibitors: Summary of a First Generation Compounds, Mini-Reviews in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/138955708786141061
DOI https://dx.doi.org/10.2174/138955708786141061 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NBS1 Heterozygosity and Cancer Risk
Current Genomics Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Expression in Coronary Artery Disease
MicroRNA The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry A TRIBUTE TO A LIVING LEGEND (Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman.)
Combinatorial Chemistry & High Throughput Screening Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Novel Thiosemicarbazide Hybrids with Amino Acids and Peptides Against Hepatocellular Carcinoma: A Molecular Designing Approach Towards Multikinase Inhibitor
Current Computer-Aided Drug Design T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets